A thirty-year retrospective study analyzing Hungarian surveillance data reveals that while polypharmacy during pregnancy declined significantly between 1980 and 2009, multiple medication exposures remained a common occurrence among expectant mothers. Researchers evaluated how maternal characteristics, age profiles, and co-occurring health conditions influenced the likelihood of pregnant individuals receiving multiple concurrent prescription therapies across different stages of gestation.
The investigation utilized extensive population-level records derived from the Hungarian Case-Control Surveillance of Congenital Abnormalities dataset, compiling health information from 89,278 total pregnancies spanning the three-decade observation interval. Investigators sought to estimate long-term prevalence rates, isolate primary maternal risk factors driving multiple medication use, and evaluate structural shifts in specific pharmacological drug classes prescribed across maternal age demographics.
Across the entire surveillance cohort, polypharmacy was recorded in 17.2 percent of women during their first trimester and affected 39.8 percent of women when evaluated across the entire duration of pregnancy. Over the course of the thirty-year timeline, these exposure rates dropped markedly, declining from 23.7 percent in the first trimester and 50.5 percent across full pregnancies during the 1980s down to 6.3 percent and 19.0 percent, respectively, by the 2000s.
To evaluate potential predictors of multi-drug exposure, the research team implemented multivariate logistic regression models that generated adjusted odds ratios across demographic and health variables. These statistical calculations demonstrated that maternal age was significantly linked to polypharmacy, with pregnant women aged 35 years or older showing greater odds of exposure during the first trimester, with an adjusted odds ratio of 1.34, and across full pregnancy, with an adjusted odds ratio of 1.28, relative to mothers aged 19 years or younger.
The presence of maternal medical conditions emerged as a substantial factor in the likelihood of being prescribed multiple concurrent medications. Expectant mothers documented with two or more acute or chronic illnesses exhibited sharply increased odds of polypharmacy, producing adjusted odds ratios exceeding 8.4 in statistical models, which underscored the direct contribution of underlying disease burden to therapeutic complexity.
Conversely, the models identified specific demographic factors associated with reduced rates of multiple drug use during pregnancy. Having a parity of one or greater was linked to lower odds of polypharmacy, and women who were unemployed or identified as low-skilled workers also demonstrated a statistically decreased likelihood of being prescribed multi-drug regimens during gestation compared to their peers.
The study demonstrated distinct patterns in how specific medication categories were distributed among different maternal age segments. For instance, the use of systemic antibacterial agents reached its highest prevalence among women aged 20 to 24 years, whereas the administration of antihypertensive drugs and antidiabetic therapies increased consistently alongside advancing maternal age.
The researchers noted that despite the substantial three-decade decrease in overall prescription exposure rates, concurrent medication use remained prevalent during pregnancy. Because advanced maternal age and multi-morbidity patterns strongly amplified medication burden across gestations, the findings demonstrate a continued need for individualized, risk-adjusted prescribing approaches throughout clinical antenatal care.
The investigation was prompted by ongoing concerns regarding potential health risks tied to medication exposure during gestation, alongside a recognized scarcity of evidence detailing how specific maternal characteristics—ranging from advancing chronological age to acute, chronic, and pregnancy-related morbidities—alter total drug burdens across pregnancy.
By analyzing thirty years of surveillance records, the researchers sought to fill these empirical gaps by tracing medication patterns across shifting decades and isolating how underlying maternal conditions drive therapeutic complexity. The observed disparities across maternal age groups, such as the peak in systemic antibacterial treatments among younger mothers aged 20 to 24 compared to higher rates of antidiabetic and antihypertensive therapies in older age brackets, illustrate how baseline health profiles shape clinical prescribing across gestations.
Because multi-morbidity and age-related health needs continue to present complex therapeutic demands, the study authors emphasized that prenatal healthcare strategies must balance the clinical management of maternal disease with careful, risk-adjusted oversight of multiple pharmaceutical treatments throughout antenatal care.
Subject of Research: Trends and maternal risk factors associated with polypharmacy during pregnancy
Article Title: Polypharmacy during pregnancy: a 30-year retrospective analysis of trends and maternal risk factors in Hungary
Article References: Ambreen, S., Dabbour, H., & Ács, N. (2026). Polypharmacy during pregnancy: a 30-year retrospective analysis of trends and maternal risk factors in Hungary. BMC Pregnancy and Childbirth. https://doi.org/10.1186/s12884-026-10205-1
Image Credits: AI Generated
DOI: 10.1186/s12884-026-10205-1
Keywords: polypharmacy, pregnancy, Hungary, maternal health, retrospective study, gestational medicine, antenatal care, maternal age, chronic morbidity, acute illness, adjusted odds ratio, multivariate logistic regression, systemic antibacterials, antihypertensives, antidiabetics, congenital abnormalities surveillance, parity, maternal risk factors
News Source: Harold Sullivan. (November 13, 2026). Polypharmacy During Pregnancy Declined Over Three Decades in Hungary Study. Scienmag.



